BioStock: Gabather poised to complete phase I with GT-002
As described in their Q2 report, despite the pandemic, Swedish biotech Gabather have taken key steps in the clinical development of its lead candidate GT-002 this year. Since the reporting period, the company has announced submitting an application for initiating a target engagement study with GT-002 in Portugal. If approved, this study will be a gateway to phase II and beyond. BioStock takes a look back at Gabather’s advancements so far this year and discusses the importance of this target engagement study with CEO Michael-Robin Witt.
Read the full interview with Michael-Robin Witt at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.